Sun Pharmaceutical Industries Signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries signs a definitive agreement to acquire Organon for USD 14 per share, valuing the deal at USD 11.75B EV. The merger aims to leverage complementary portfolios and global scale for long-term growth.
Pharmaceutical Merger And Acquisition | 27/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy